Skip to main content



09-13-2017 | Acarbose | EASD 2017 | News

ACE results suggest no reduction in CV risk with acarbose treatment

The α-glucosidase inhibitor acarbose does not reduce cardiovascular risk but could decrease the risk for developing type 2 diabetes among patients with coronary heart disease and impaired glucose tolerance, results of the phase IV placebo-controlled ACE trial suggest.

Read more

Related topics



Journal articles and book chapters

10-11-2017 | Cardiovascular disorders | Review | Article

Updates on cardiovascular outcome trials in diabetes

This review summarizes the results of the DEVOTE, CANVAS, EXSCEL, and ACE trials that tested the cardiovascular safety of insulin degludec, canagliflozin, once-weekly exenatide, and acarbose, respectively.

Schnell O et al. Cardiovasc Diabetol 2017;16:128. doi:10.1186/s12933-017-0610-y

07-31-2017 | Prevention | Review | Article

Pharmaceutical interventions for diabetes prevention in patients at risk

In this review, Chatterjee et al. discuss the various glucose-lowering and other pharmaceutical interventions that have been tested for diabetes prevention and their use in real world settings.

Chatterjee S, Davies M, Khunti K. Am J Cardiovasc Drugs 2017. doi:10.1007/s40256-017-0239-y